Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.60 |
| ▸ | CA12 | O43570 | 14/20 | 0.60 |
| ▸ | CA1 | P00915 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892747 | 0.93 | CA9 (0.58) | CA9CA12CA1KDM4EHTT | |
| SCHEMBL2892758 | 0.85 | MAPT (0.53) | CA9CA12CA1KDM4EHTT | |
| SCHEMBL6349448 | 0.80 | CA9 (0.67) | CA9CA12CA1SMN1; SMN2CA2 | |
| SCHEMBL6710361 | 0.78 | GPR35 (0.48) | KDM4EHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL6711857 | 0.77 | ALDH1A1 (0.46) | KDM4EHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2893220 | 0.76 | CA9 (0.55) | CA9CA12CA1KDM4EHTT | |
| SCHEMBL2885184 | 0.75 | CA2 (0.48) | CA9CA12CA1MEN1KMT2A | |
| SCHEMBL1307860 | 0.74 | GPR35 (0.56) | MEN1KMT2ATP53 | |
| SCHEMBL19554168 | 0.73 | KCNMA1 (0.43) | SMN1; SMN2LMNAALOX15 | |
| SCHEMBL6710157 | 0.72 | ALDH1A1 (0.40) | KDM4EHTTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | claimed |
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNA2, KCNJ2, KCNB2 | CA9 4618/4885CA12 4620/4885CA1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.